enGene Therapeutics Inc. reports results for the quarter ended July 31 - Earnings Summary

enGene Therapeutics

09/09/2026 13:25

enGene Therapeutics Inc. ENGN.OQ reported a quarterly adjusted loss of 47 cents​​ per share for the quarter ended July 31, higher than the same quarter last year, when the company reported EPS of -57 cents.  The mean expectation of eleven analysts for the quarter was for a loss of 43 cents per share. Wall Street expected results to range from -51 cents to -38 cents per share.
Reported revenue was zero​; analysts expected zero. 
enGene Therapeutics Inc.'s reported EPS for the quarter was a loss of 47 cents​.
The company reported a quarterly loss of $32.5 million.
enGene Therapeutics Inc. shares had risen by 11.0% this quarter and lost 78.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 14.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for enGene Therapeutics Inc. is $4.00, about 52% above its last closing price of $1.92
This summary was machine generated from LSEG data September 9 at 12:25 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jul. 31 2026 
-0.43
-0.47
Missed
Apr. 30 2026 
-0.47
-0.43
Beat
Jan. 31 2026 
-0.56
-0.44
Beat
Oct. 31 2025 
-0.57
-0.73
Missed